Cisplatin-associated anemia: An erythropoietin deficiency syndrome

Journal of Clinical Investigation

Volumn 95, Issue 4, 1995, Pages 1650-1659

  Wood, Patricia A ^a   Hrushesky, William J M ^a,b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b STRATTON VA MEDICAL CENTER   (United States)

Author keywords

anemia; cancer; cisplatin; erythropoietin; kidney

Indexed keywords

CISPLATIN; CREATINE; DOXORUBICIN; ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG INDUCED DISEASE; ERYTHROPOIESIS; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; IATROGENIC DISEASE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; MALE; NEPHROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; SYNDROME DELINEATION;

EID: 0028949432     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI117840     Document Type: Article

References (53)

1. Koury, S. T., M. C. Bondurant, and M. J. Koury. 1988. Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization. Blood. 71:524-527.
2. Lacombe, C., J. L. Silva, P. Bruneval, J. G. Fournier, F. Wendling, C. Casadevall, J. P. Camilleri, J. Bariety, B. Varet, and P. Tambourin. 1988. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J. Clin. Invest. 81:620-623.
3. Loya, F., Y. Yang, H. Lin, E. Goldwasser, and M. Albitar. 1994. Transgenic mice carrying the erythropoietin gene promoter linked to lac Z express the reporter in proximal convoluted tubule cells after hypoxia. Blood. 84:1831-1836.
4. Adamson, J. W., J. W. Eschbach, and C. A. Finch 1968. The kidney and erythropoiesis. Am. J. Med. 44:725-733.
5. Neilson, O. V., and J. H. Thaysen. 1989. Erythropoietin deficiency in acute renal failure. Lancet i:624.
6. Lim, V. S., R. L. DeGowin, and D. Zavala. 1989. Recombinant human erythropoietin treatment in predialysis patients. Ann. Intern. Med. 110:108-114.
7. Winerals, C. G., D. O. Oliver, M. J. Pippard, C. Reid, M. R. Dowing, and P. M. Cotes. 1986. Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet. ii:1175-1178.
8. Matsumoto, T., K. Endoh, K. Kamisango, K. I. Akamatsu, K. Koizumi, M. Higuchi, N. Imai, H. Mitsui, and T. Kawagueti. 1990. Effect of recombinant human erythropoietin on anticancer drug-induced anemia. Br. J. Haematol. 75:463-468.
9. Nowrousian, M. R., and C. G. Schmidt. 1982. Effects of cisplatin on different haemopoietic progenitor cells in mice. Br. J. Cancer. 46:397-402.
10. Wood, P. A., and W. J. M. Hrushesky. 1984. Cisplatin-induced anemia: an erythropoietin deficiency syndrome. Proc. Am. Soc. Clin. Oncol. 3:154a. (Abstr.)
11. Wiltshaw, E., and T. Kroner. 1976. Phase II study of cis-dichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat. Rep. 60:55-60.
12. Rossof, A. H., R. E. Slayton, and C. P. Perlia. 1972. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP). Cancer. 30:1451-1456.
13. Klaussen, D. K., and J. L. Spivak. 1990. Hepatitis-related erythropoietin production. Am. J. Med. 89:684-686.
14. Hrushesky, W. J. M., F. Lévi, F. Halberg, and B. J. Kennedy. 1982. Orcadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats. Cancer Res. 42:945-949.
15. Hrushesky, W. J. M., R. Borch, and F. Levi. 1982. Circadian time dependence of cisplatin urinary kinetics. Clin. Pharmacol. Ther. 32:330-339.
16. Dentino, M., R. C. Luft, N. M. Yum, D. S. Williams, and L. H. Einhorn. 1978. Long term effects of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer. 41:1274-1281.
17. Fjeldborg, P., J. Sorensen, and P. E. Helkjaer. 1986. The long-term effect of cisplatin on renal function. Cancer. 58:2214-2217.
18. Faquin, W. C., T. J. Schneider, and M. A. Goldberg. 1992. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood. 79:1987-1994.
19. Means, R. A., and S. B. Krantz. 1991. Inhibition of human erythroid colony-forming units by gamma-interferon can be corrected by recombinant human erythropoietin. Blood. 78:2564-2567.
20. Johnson, R. A., T. A. Waddelow, J. Caro, and G. D. Roodman. 1989. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood. 74:130-138.
21. Means, R. T., and S. B. Krantz. 1992. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 80:1639-1647.
22. Gonzalez-Vitale, J. C., D. M. Hayes, E. Cvitkovic, and S. S. Sternberg. 1977. The renal pathology in clinical trials of cis-platinum (II) diamminedichloride. Cancer. 39:1362-1371.
23. Barton, C. H., M. Pahl, N. D. Vaziri, and T. Cesario. 1984. Renal magnesium wasting associated with amphotericin B therapy. Ann. Intern. Med. 77:471-474.
24. Getaz, E. P., S. Beckley, J. Fritzpatrick, and A. Dozier. 1980. Cisplatin-induce hemolysis. N. Engl. J. Med. 302:334-335.
25. Abels, R. I., K. M. Larholt, K. D. Krantz, and B. C. Bryant. 1991. Recombinant human erythropoietin (r-HuEPO) for the treatment of the anemia of cancer. In Blood Cell Growth Factors: Their Present and Future Use in Hematology and Oncology. M. J. Murphy, editor. Alpha Medical Press, Dayton, OH. 121-141.
26. Miller, C. B., L. C. Platanias, S. R. Mills, M. L. Zahurak, M. J. Ratin, D. S. Ettinger, and R. J. Jones. 1992. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J. Natl. Cancer Inst. 84:98-103.
27. James, R. D., P. M. Wilkinson, F. Belli, R. Welch, and R. Cowan. 1992. Recombinant human erythropoietin in patients with ovarian carcinoma and anemia secondary to cisplatin and carboplatin chemotherapy: preliminary results. Acta Haematol. 87:12-15.
28. Cascinu, S., A. Fedeli, E. Del Ferro, S. L. Fedeli, and G. Catalono. 1994. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J. Clin. Oncol. 12:1058-1062.
29. Hayes, D. M., E. Cvitkovic, R. B. Golbey, E. Scheiner, L. Helson, and I. Krakoff. 1977. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 39:1372-1381.
30. Gandara, D. R., H. Wold, E. A. Perez, A. B. Diesseroth, J. Doroshow, F. Meyers, K. McWhiter, J. Hannigan, and M. W. Degregorio. 1989. Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. J. Natl. Cancer Inst. 81:790-794.
31. Kociba, R. J., and S. D. Sleight. 1971. Acute toxicologic and pathologic effects of cis-diammine dichloroplatinum (NSC-119875) in the male rat. Cancer Chemother. Rep. 555:1-8.
32. Teicher, B. A., S. A. Holden, J. P. Eder, T. W. Brann, S. M. Jones, and E. Frei. 1989. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res. 49:5994-5998.
33. Smith, D. H., E. Goldwasser, and E. E. Vokes. 1991. Serum immunoerythropoietin levels in patients with cancer receiving cisplatin-based chemotherapy. Cancer. 68:1101-1105.
34. Kuzar, M. E. 1980. Cisplatin-induced anemia. N. Engl. J. Med. 303:110.
35. Henry, D., R. Nelson, B. Brooks, R. Jacobson, S. Jones, A. Keller, J. Kugler, J. Moore, C. Nichols, R. Silver, A. Stoddon, B. Mason, R. Abels, and S. Rudnick. 1991. Prospective evaluation of transfusion (Tx) requirements for anemic cancer patients +/- chemorx. Blood. 78:152a. (Abstr.)
36. Lee, G. R. 1983. The anemia of chronic disease. Semin. Hematol. 20:61-80
37. Cotes, M. P., M. J. Pippard, C. D. L. Reid, C. G. Winerals, D. O. Oliver, and J. P. Royston. 1989. Characterization of the anemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Quart. J. Med. 70:113-137.
38. Hughes, R. T., P. M. Cotes, M. J. Pippard, J. M. Stevens, D. O. Oliver, C. G. Winerals, and J. P. Poyston. 1990. Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment. Br. J. Haematol. 75:268-273.
39. Koury, M. J., and M. C. Bondurant. 1990. Erythropoietin retards breakdown and prevents death in erythroid progenitor cells. Science (Wash. DC). 248:378-381.
40. Platanias, L. C., C. B. Miller, R. Mick, R. D. Hart, H. Ozer, J. M. McEvilly, R. J. Jones, and M. J. Ratain. 1991. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J. Clin. Oncol. 9:2021-2026.
41. Case, D., M. Bukowski, R. W. Carey, E. H. Fishkin, D. H. Henry, R. J. Jacobson, S. E. Jones, A. M. Keler, J. W. Kugler, C. R. Nichols, S. E. Salmon, R. T. Silver, A. M. Storniolo, G. L. Wampler, C. M. Dooley, K. M. Larholt, R. A. Nelson, and R. I. Abels. 1993. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J. Natl. Cancer Inst. 85:801-806.
42. Miller, C. B., R. J. Jones, S. Piantadosi, M. D. Abeloff, and J. L. Spivak. 1990. Decreased erythropoietin response in patients with the anemia of cancer. N. Engl. J. Med. 322:1689-1692.
43. Lin, A. C., E. Goldwasser, E. M. Bernard, and S. W. Chapman. 1990. Amphotericin B blunts erythropoietin response to anemia. J. Infect. Dis. 161:348-351.
44. Ishikawa, T., and F. Ali-Osman. 1993. Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J. Biol. Chem. 268:20116-20125.
45. Robins, A. B., and M. O. Leach. 1983. Pharmacokinetics of therapeutic doses of isotopically labelled platinum antitumor agents in the mouse and rat. Cancer Treat. Rep. 67:245-252.
46. Leroy, A. F., R. J. Lutz, R. L. Dedrick, C. L. Litterst, and A. M. Guarino. 1979. Pharmacokinetic study of cis-dichlorodiammineplatinum (II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic milieu. Cancer Treat. Rep. 63:59-71.
47. Litterst, C. L., and V. G. Schweitzer. 1984. Increased tissue deposition and decreased excretion of platinum following administration of cisplatin to cisplatin-treated animals. Cancer Chemother. Pharmacol 12:46-49.
48. El-Sharkawi, A. M., W. D. Morgan, S. Cobbold, M. B. M. Jaib, C. J. Evans, L. J. Somervaille, D. R. Chettle, and M. C. Scott. 1986. Unexpected mobilization of lead during cisplatin chemotherapy. Lancet. i:249-250.
49. Hart, B., G. C. Farrell, W. G. E. Cooksley, and L. W. Powell. 1976. Enhanced drug metabolism in cigarette smokers. Br. Med. J. 2:147-149.
50. Kjellstrom, T. 1979. Exposure and accumulation of cadmium in populations from Japan, the United States and Sweden. Environ. Health Perspect. 28:169-197.
51. Friberg, L., and M. Vahter. 1983. Assessment of exposure to lead and cadmium through biological monitoring. Results of a UNEP/WHO global study. Environ. Res. 30:95-128.
52. Naganumara, A., M. Satoh, and N. Imura. 1987. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum (II) by induction of metallothionein synthesis without compromising its antitumor activity. Cancer Res. 47:983-987.
53. Teicher, B. A., T. S. Herman, S. A. Holden, Y. Wang, M. R. Pfeffer, J. W. Crawford, and E. Frei. 1990. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (Wash. DC). 247:1457-1461.